Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
This phase I trial identifies the best dose and clinical benefit of giving pemigatinib
following standard induction chemotherapy in patients with newly diagnosed acute myeloid
leukemia. Pemigatinib selectively inhibits FGFR (fibroblast growth factor receptor) activity,
a receptor that may contribute to the growth of leukemia cells. The genetic changes
responsible for activating the growth of leukemia cells can be unique to each patient and can
change during the course of the disease. Chemotherapy drugs, such as cytarabine and
daunorubicin work in different ways to stop the growth of cancer cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading.
Phase:
Phase 1
Details
Lead Sponsor:
OHSU Knight Cancer Institute
Collaborators:
Incyte Corporation Oregon Health and Science University